Genetic Analysis (Norway)
We have core competence in detecting microorganisms like bacteria and viruses in stool and have the ability to develop In Vitro Diagnostic tests in all diseases where microbiota is involved. We are the first company in the world to develop, document, clinically validate and commercialize a CE-marked In Vitro Diagnostic test (GA-map® Dysbiosis Test Lx) for diagnosis and characterizing of dysbiosis in IBS and IBD patients. Our test has been used in 50 clinical trials and reported in 25+ scientific
Basic Information
- Category: business
- Website: http://www.genetic-analysis.com/
Documented Facts
- Email: info@genetic-analysis.com (No linked source recorded for this statement.)
Evidence and Sources
- Genetic Analysis (Norway) — Official Site (official)
- Genetic Analysis (Norway) on facebook (social)
- Genetic Analysis (Norway) on linkedin (social)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Genetic Analysis (Norway).
- Canonical profile: https://brandsource.ai/brands/genetic-analysis-norway
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/genetic-analysis-norway/json-ld
- Citation profile API: https://brandsource.ai/api/brands/genetic-analysis-norway/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (85/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
We have core competence in detecting microorganisms like bacteria and viruses in stool and have the ability to develop In Vitro Diagnostic tests in all diseases where microbiota is involved. We are the first company in the world to develop, document, clinically validate and commercialize a CE-marked In Vitro Diagnostic test (GA-map® Dysbiosis Test Lx) for diagnosis and characterizing of dysbiosis in IBS and IBD patients. Our test has been used in 50 clinical trials and reported in 25+ scientific
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.